152 related articles for article (PubMed ID: 27150639)
1. Circulating Tumor DNA as a Marker of Therapeutic Response in Patients With Renal Cell Carcinoma: A Pilot Study.
Ball MW; Gorin MA; Guner G; Pierorazio PM; Netto G; Paller CJ; Hammers HJ; Diaz LA; Allaf ME
Clin Genitourin Cancer; 2016 Oct; 14(5):e515-e520. PubMed ID: 27150639
[No Abstract] [Full Text] [Related]
2. [Serum gamma-enolase as a marker for renal cell carcinoma].
Takashi M; Tanaka J; Mitsuya H; Murase T; Haimoto H; Kato K
Nihon Hinyokika Gakkai Zasshi; 1988 Feb; 79(2):220-6. PubMed ID: 3225998
[No Abstract] [Full Text] [Related]
3. Potential of circulating tumor DNA as a predictor of therapeutic responses to immune checkpoint blockades in metastatic renal cell carcinoma.
Kim YJ; Kang Y; Kim JS; Sung HH; Jeon HG; Jeong BC; Seo SI; Jeon SS; Lee HM; Park D; Park WY; Kang M
Sci Rep; 2021 Mar; 11(1):5600. PubMed ID: 33692449
[TBL] [Abstract][Full Text] [Related]
4. Serum vascular endothelial growth factor is a candidate biomarker of renal cell carcinoma in hemodialysis patients.
Ishizuka T; Hayashi T; Nakazawa H; Ito F; Nitta K; Horita S; Uchida K; Nihei H; Toma H
Nephron; 2000 Jan; 84(1):83-4. PubMed ID: 10644915
[No Abstract] [Full Text] [Related]
5. Metastatic clear cell renal cell carcinoma: Circulating biomarkers to guide antiangiogenic and immune therapies.
Zhang T; Zhu J; George DJ; Nixon AB
Urol Oncol; 2016 Nov; 34(11):510-518. PubMed ID: 27498927
[TBL] [Abstract][Full Text] [Related]
6. Editorial Comment to Potential tumor markers of renal cell carcinoma: α-enolase for postoperative follow up, and galectin-1 and galectin-3 for primary detection.
Ornellas AA
Int J Urol; 2013 May; 20(5):535-6. PubMed ID: 23113761
[No Abstract] [Full Text] [Related]
7. Is Change in Hemoglobin Level a Predictive Biomarker of Tyrosine Kinase Efficacy in Metastatic Renal Cell Carcinoma? A Turkish Oncology Group Study.
Bilir C; Yıldız İ; Bilici A; Ucar M; Berk V; Yıldız Y; Yazıcı O; İmamoğlu Gİ; Karadurmuş N; Pilancı KN; Arpacı E; Tanrıverdi Ö; Karcı E; Temiz S; Nayır E; Oktay E; Dal P; Petekkaya İ; Varım C; Cinemre H
Cancer Invest; 2017 Apr; 35(4):248-255. PubMed ID: 28333566
[TBL] [Abstract][Full Text] [Related]
8. Serum iron as a tumor marker in renal cell carcinoma.
Yu CC; Chen KK; Chen MT; Huang JK; Lin AT; Lee YH; Chang LS
Eur Urol; 1991; 19(1):54-8. PubMed ID: 2007419
[TBL] [Abstract][Full Text] [Related]
9. Serum and urine biomarkers for human renal cell carcinoma.
Pastore AL; Palleschi G; Silvestri L; Moschese D; Ricci S; Petrozza V; Carbone A; Di Carlo A
Dis Markers; 2015; 2015():251403. PubMed ID: 25922552
[TBL] [Abstract][Full Text] [Related]
10. Tumor Cell-Free DNA Copy Number Instability Predicts Therapeutic Response to Immunotherapy.
Weiss GJ; Beck J; Braun DP; Bornemann-Kolatzki K; Barilla H; Cubello R; Quan W; Sangal A; Khemka V; Waypa J; Mitchell WM; Urnovitz H; Schütz E
Clin Cancer Res; 2017 Sep; 23(17):5074-5081. PubMed ID: 28320758
[No Abstract] [Full Text] [Related]
11. Combination of MiR-378 and MiR-210 Serum Levels Enables Sensitive Detection of Renal Cell Carcinoma.
Fedorko M; Stanik M; Iliev R; Redova-Lojova M; Machackova T; Svoboda M; Pacik D; Dolezel J; Slaby O
Int J Mol Sci; 2015 Sep; 16(10):23382-9. PubMed ID: 26426010
[TBL] [Abstract][Full Text] [Related]
12. Dissecting responsive phenotypes through cytokine and angiogenic factor analysis.
Rini B
Ann Oncol; 2012 Jan; 23(1):6-7. PubMed ID: 22100695
[No Abstract] [Full Text] [Related]
13. Role of Biomarkers in Prediction of Response to Therapeutics in Metastatic Renal-Cell Carcinoma.
Adashek JJ; Salgia MM; Posadas EM; Figlin RA; Gong J
Clin Genitourin Cancer; 2019 Jun; 17(3):e454-e460. PubMed ID: 30733185
[TBL] [Abstract][Full Text] [Related]
14. Serum ferritin as a clinical marker for renal cell carcinoma: influence of tumor size and volume.
Kirkali Z; Güzelsoy M; Mungan MU; Kirkali G; Yörükoglu K
Urol Int; 1999; 62(1):21-5. PubMed ID: 10436426
[TBL] [Abstract][Full Text] [Related]
15. Reduced cytosolic carboxypeptidase 6 (CCP6) level leads to accumulation of serum polyglutamylated DNAJC7 protein: A potential biomarker for renal cell carcinoma early detection.
Li C; Wang J; Hao J; Dong B; Li Y; Zhu X; Ding J; Ren S; Zhao H; Wu S; Tian Y; Wang GQ
Oncotarget; 2016 Apr; 7(16):22385-96. PubMed ID: 26993597
[TBL] [Abstract][Full Text] [Related]
16. Circulating biomarkers and outcome from a randomised phase II trial of sunitinib vs everolimus for patients with metastatic renal cell carcinoma.
Voss MH; Chen D; Marker M; Hakimi AA; Lee CH; Hsieh JJ; Knox JJ; Voi M; Motzer RJ
Br J Cancer; 2016 Mar; 114(6):642-9. PubMed ID: 26908330
[TBL] [Abstract][Full Text] [Related]
17. Changes in circulating pro-angiogenic cytokines, other than VEGF, before progression to sunitinib therapy in advanced renal cell carcinoma patients.
Porta C; Paglino C; Imarisio I; Ganini C; Sacchi L; Quaglini S; Giunta V; De Amici M
Oncology; 2013; 84(2):115-22. PubMed ID: 23154434
[TBL] [Abstract][Full Text] [Related]
18. Functional analysis of serum microRNAs miR-21 and miR-106a in renal cell carcinoma.
Tusong H; Maolakuerban N; Guan J; Rexiati M; Wang WG; Azhati B; Nuerrula Y; Wang YJ
Cancer Biomark; 2017; 18(1):79-85. PubMed ID: 27814278
[TBL] [Abstract][Full Text] [Related]
19. SCUBE1: a promising biomarker in renal cell cancer.
Karagüzel E; Menteşe A; Kazaz İO; Demir S; Örem A; Okatan AE; Altay DU; Yaman SÖ
Int Braz J Urol; 2017; 43(4):638-643. PubMed ID: 28379666
[TBL] [Abstract][Full Text] [Related]
20. Grail to pour $1 billion into blood test to detect early cancer.
Sheridan C
Nat Biotechnol; 2017 Feb; 35(2):101-102. PubMed ID: 28178244
[No Abstract] [Full Text] [Related]
[Next] [New Search]
